Sircar G, et al. - Authors compared the effectiveness and safety of rituximab (RTX) vs CYC in retarding the progression of interstitial lung disease and skin manifestations of primary SSc. Sixty patients of dcSSc, age 18–60 years with skin and lung involvement were randomly assigned to monthly pulses of CYC 500 mg/m² or RTX 1000 mg × 2 doses at 0, 15 days. Findings suggested that in the primary therapy of skin and lung manifestations of scleroderma, RTX is a safe and effective alternative to CYC. Experts noted that the serious adverse events were more common in the CYC group.